Pulmonary tuberculosis in the immunocompromised patients
Abstract
Background/Aim. During the last few decades, immunocompromising diseases led to an increase in the number of tuberculosis cases. The aim of this study was to examine the influence of immunocompromising diseases on the course of tuberculosis. Methods. The research included two groups, each consisting of 40 subjects with tuberculosis, who were treated at the Institute for Pulmonary Diseases of Vojvodina during 2010 and 2011. The first group had no immunocompromising diseases (the kontrol group), whereas the second group contained patients with accompanying immunocompromising diseases. The data from the patients’ medical history, from the Center for Microbiology and from the Radiology Center were used. The two groups were compared according to the following characteristics: age, sex, bacteriological status, radiological presence of the disease, presence of adverse effects of drugs, presence of resistance to drugs, duration of the therapy regimen and the duration of hospitalization. Results. The group of immunocompromised patients was older in average than the control group and included a higher percentage of males. The immunocompromised group had statistically important longer average time required for the sputum smear conversion (p = 0.000) and for the conversion of sputum cultures to M. tuberculosis (p = 0.010), more frequent presence of cavity (p = 0.030), longer average therapy regimen duration (p = 0.000) and higher average number of hospital days (p = 0.000) compared to the control group. The most frequent localization of changes in the immunocompromised patients was in all lobes of both lungs (32.5%) whereas the changes in the control group were mostly localized in the upper lung lobes (62.5%). There was no statistically important difference in the finding of sputum smear positive acid-fast bacilli on direct micoscropy, the presence of adverse effects of drugs and M. tuberculosis resistance to drugs between the two groups of patients. Conclusion. The immunocompromising diseases change the course of tuberculosis, primarily by affecting bacteriological status, radiological presentation, the length of therapy regimen and the duration of hospitalization.
References
Hauck FR, Neese BH, Panchal AS, El-Amin W. Identification and management of latent tuberculosis infection. Am Fam Physician 2009; 79(10): 879‒86.
Butt G, Altaf F, Hussain I. Pulmonary tuberculosis in dermato-logical patients on high-dose, long-term steroid therapy. J Pak Assoc Derma 2015; 15(2): 119‒31.
Oh YW, Effmann EL, Godwin JD. Pulmonary infections in im-munocompromised hosts: The importance of correlating the conventional radiologic appearance with the clinical setting. Radiology 2000; 217(3): 647‒56.
Okafor UH. Pattern of clinical presentations in immunocom-promised patient. In: Metodiev K, Immunodeficiency. Rijeka, Croaia: In Tech; 2012.
Grbac I, Smolčić S, Jurman D, Broz S. Clinical picture of pulmo-nary tuberculosis at the end of the second millennium. Acta Clin Croat 2000; 39: 175‒9.
Euroean Centre for Disease Prevention and Control. Use of inter-feron-gamma release assays in support of TB diagnosis. Stock-holm: ECDC; 2011.
Gooze L, Daley CL. Tuberculosis and HIV: HIV in Site Knowledge Base Chapter. San Francisco: University of Cali-fornia; 2013.
Kisembo HN, Boon DS, Davis JL, Okello R, Worodria W, Catta-manchi A, et al. Chest radiographic findings of pulmonary tu-berculosis in severely immunocompromised patients with the human immunodeficiency virus. Br J Radiol 2012; 85(1014): e130‒9.
Kumar N, Kedarisetty CK, Kumar S, Khillan V, Sarin SK. An-titubercular therapy in patients with cirrhosis: challenges and options. World J Gastroenterol 2014; 20(19): 5760‒72.
Mimi N, Medregoniu D, Olteanu M, Golli A, Olteanu M, Maceseanu A, et al. Tuberculosis and chronic renal failure; therapy patterns. Curr Health Sci J 2011; 37(2): 106‒8.
Malhotra KK. Treatment of tuberculosis in chronic renal fail-ure, maintenance dialysis and renal transplant. Indian J Neph-rol 2003; 13: 69‒71.
Gardam M, Iverson K. Rheumatoid arthritis and tuberculosis: time to take notice. J Rheumatol 2003; 30(7): 1397‒9.
Miras MD, Tenorio CH, Alonso JJ. Tuberculosis in patients with Systemic Lupus Erythematosus: Spain's situation. Reumatol Clin 2013; 9(6): 369‒72.
Borekci S, Atahan E, Demir YD, Mazıcan N, Duman B, Ozguler Y, et al. Factors affecting the tuberculosis risk in patients re-ceiving anti-tumor necrosis factor-α treatment. Respiration 2015; 90(3): 191‒8.
Silva DG, Silva BD, Junqueira-Kipnis AP, Rabahi MF. Tubercu-losis in rheumatoid arthritis patients: The difficulty in making the diagnosis of latent infection. J Bras Pneumol 2010; 36(2): 243‒51. (Portuguese)
Karnak D, Kayacan O, Beder S. Reactivation of pulmonary tu-berculosis in malignancy. Tumori 2002; 88(3): 251‒4.
Happel KI, Nelson S. Alcohol, immunosuppression, and the lung. Proc Am Thorac Soc 2005; 2(5): 428‒32.
Suhadev M, Thomas BE, Murugesan P, Chandrasekaran V, Charles N, Durga R, et al. Alcohol use disorders(AUD) among tuber-culosis Patients: A study from Chennai, South India. PLoS ONE 2011; 6(5): e19485.
Lönorth K, Williams BG, Stadlin S, Jaramillo E, Dye C. Alchocol use as risk factor for tuberculosis-a systematic review. BMC Public Health 2008; 8: 289.
Vasantha R, Sridevi S, Sudhakar G. Association between smok-ing, alcoholism and pulmonary tuberculosis. Int J Sci Res 2015; 4(6): 516‒8.
Yurteri G, Sarac S, Dalkilic O, Ofluoglu H, Demiröz OF. Features of pulmonary tuberculosis in patients with diabetes mellitus: A comparative study. Ch Hop Ýst Turk 2004; 1: 5‒8.
Golubović S, Đorđević I, Radović M, Pejović G, Stanković I. Im-portance of early diagnosis of low respiratory tract infections in patients with diabetes mellitus. Acta Fac Med Naiss 2005; 22(3): 139‒44.
Guptan A, Shah A. Tuberculosis and diabetes: An appraisal. Ind J Tub 2000; 47(1): 3‒8.
Ljubić S, Balachandran A, Pavlić-Renar I, Barda A, Metelko Ž. Pulmonary infections in diabetes mellitus. Diabetolpgia Croat 2004; 33(4): 115‒24.
Kiyan E, Kilicaslan Z, Gurgan M, Tunaci A, Yildiz A. Clinical and radiographic features of pulmonary tuberculosis in non-AIDS immunocompromised patients. Int J Tuberc Lung Dis 2003; 7(8): 764‒70.
Perez-Guzman C, Torres-Cruz A, Villarreal-Velarde H, Vargas MH. Progressive age-related changes in pulmonary tuberculo-sis images and the effect of diabetes. Am J Respir Crit Care Med 2000; 162(5): 1738‒40.
Singla R, Khan N, Al-Sharif N, Ai-Sayegh MO, Shaikh MA, Os-man MM. Influence of diabetes on manifestations and treat-ment outcome of pulmonary TB patients. Int J Tuberc Lung Dis 2006; 10(1): 74‒9.
Jabbar A, Hussain SF, Khan AA. Clinical characteristics of pulmonary tuberculosis in adult Pakistani patients with co-existing diabetes mellitus. East Mediterr Health J 2006; 12(5): 522‒7.
Fiske CT, Hamilton CD, Stout JE. Alchocol use and clinical manifestations of tuberculosis. J Infect 2009; 58(5): 395‒401.
Bacakoğlu F, Başoğlu OK, Cok G, Sayiner A, Ateş M. Pulmonary tuberculosis in patients with diabetes mellitus. Respiration 2001; 68(6): 595‒600.
Arbex MA, Varella Mde C, Siqueira HR, Mello FA. An-tituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs. J Bras Pneumol 2010; 36(5): 626‒40. (English, Portuguese)
Kanabus AInformation about Tuberculosis: TB Statistics-Global, Regional and High Burden. Global Health Education (GHE); 2016. Available from: www.tbfacts.org.
Bashar M, Alcabes P, Rom WN, Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest 2001; 120(5): 1514‒9.